NCT02000427 2024-05-28Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic LeukemiaAmgenPhase 2 Completed45 enrolled 24 charts 2 FDA
NCT03109093 2023-03-21Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic LeukemiaGoethe UniversityPhase 2 Completed83 enrolled